Robbins LLP is Investigating Allegations that Nano-X Imaging Ltd. (NNOX) Misled Investors Regarding Its Manufacturing Operations and Financial Condition

Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Nano-X Imaging Ltd. (NASDAQ: NNOX) securities between March 31, 2025 and April 17, 2026. Nano-X Imaging Ltd. develops a commercial-grade tomographic imaging device with a digital X-ray source.

The Allegations:

According to the complaint, during the class period, defendants made materially false and misleading statements regarding the Company’s business, operations, and prospects. Specifically, defendants made false and/or misleading statements and/or failed to disclose that: (i) defendants overstated purported efficiency gains achieved in Nano- X’s operations, as well as the purported increased demand for its products; (ii) in reality, Nano-X’s production and manufacturing operations were poorly aligned with demand for the Company’s products; (iii) as a result, Nano-X was experiencing significantly increased operating expenses and cash burn; (iv) the foregoing significantly increased the likelihood that Nano-X would be forced to take disruptive remedial measures with respect to its manufacturing operations, entailing significant restructuring and impairment charges; and (v) as a result, defendants’ public statements were materially false and misleading at all relevant times.

Plaintiff alleges that on April 20, 2026, when Nano-X issued a press release announcing its fourth quarter (“Q4”) 2025 financial results and business updates. Therein, Nano-X reported, inter alia, a Q4 net loss of $33.4 million, mainly due to a $17.5 million charge attributed to impairment of long-lived following a restructuring initiative at its Korean chip manufacturing facility. In explaining the restructuring charge, the press release acknowledged that Nano-X needed to “shift[] to a more efficient outsourced production model that is better aligned with current and anticipated demand.” The same press release also announced that Nano-X’s then-Chief Financial Officer (“CFO”), Defendant Ran Daniel (“Daniel”), would step down as CFO, effective July 31, 2026. On this news, the price of Nano-X’s stock price fell $0.695 per share, or 24.39%, to close at $2.155 per share on April 20, 2026.

What Now: You may be eligible to participate in the class action against Nano-X Imaging Ltd. Shareholders who wish to serve as lead plaintiff for the class should contact Robbins LLP. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation.  You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.